Using a harmless glucose solution, the procedure generates reliable results

May 2, 2023 — Metabolic disorders are involved in many common health conditions such as Alzheimer's, depression, diabetes, and cancer. Non-invasive diagnostic methods are needed to reliably detect these disorders. Until now, radioactive substances have been used to map glucose metabolism in the brain. However, a research team at MedUni Vienna has developed a new MRI approach that uses a harmless glucose solution to generate reliable results. This new method can be used with all common MRI scanners and has been published in the scientific journal Nature Biomedical Engineering. 

The research team conducted a study to improve current diagnostic methods for mapping brain glucose metabolism. They measured blood glucose levels and metabolic products in healthy subjects multiple times over 90 minutes, using a harmless glucose solution instead of radiolabeled glucose. This method indirectly measured the concentrations and metabolism of glucose based on changes in signal intensity for the product. Unlike other approaches, this method does not require additional hardware components, making it easy to use with other MRI devices. Wolfgang Bogner from MedUni Vienna explained the significance of this finding for clinical practice. 

 

Broad Range of Potential Applications 

The study was conducted by researchers from the Department of Psychiatry and Psychotherapy and the Department of Medicine III at MedUni Vienna, using the university's 7-Tesla MRI scanner, which is the only ultra-high-field MR scanner in Austria. The researchers were able to demonstrate that their new approach also works on 3-Tesla MR scanners, which are commonly used in clinical applications. This finding was an important step in validating the practicality and widespread applicability of the new method. Fabian Niess, the lead author of the follow-up study, highlighted the significance of this development. 

 

Further Studies Needed to Confirm Results 

Many common diseases are characterized by abnormalities in glucose metabolism. For example, cancer and tumor cells consume more glucose than normal cells, which is used in diagnosing and locating tumors through PET-CT scans. However, this requires injecting patients with radioactive glucose. While the new, less invasive MRI method developed at MedUni Vienna shows promise, further studies are needed to validate its effectiveness before it can be used for patient benefit. 

For more information: https://www.meduniwien.ac.at/web/ 


Related Content

News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
News | Radiology Business

May 29, 2024 — Strategic Radiology added a third California member to the nation’s leading coalition of independent ...

Time May 29, 2024
arrow
News | Lung Imaging

May 24, 2024 — Smokers who have small abnormalities on their CT scans that grow over time have a greater likelihood of ...

Time May 24, 2024
arrow
News | Artificial Intelligence

May 21, 2024 — According to a newly-published study of nearly 5,000 screening mammograms interpreted by an FDA-approved ...

Time May 21, 2024
arrow
News | Point-of-Care Ultrasound (POCUS)

May 20, 2024 — Exo (pronounced “echo”), a medical imaging software and devices company, announced the release of Exo ...

Time May 20, 2024
arrow
News | Cardiac Imaging

May 17, 2024 — The Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual Meeting found that the ...

Time May 17, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
News | Radiology Imaging

May 13, 2024 — National Basketball Association (NBA), the National Basketball Players Association (NBPA), and the Next ...

Time May 13, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
Subscribe Now